Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DoximityDOCS -2.35%86 Future 3-5Y EPS without NRI Growth Rate is 6.42 as of Aug. 24, 2026. GuruFocus rates DOCS with a GF Score™ of 86/100 and a GF Value™ of $45.46 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 198 Healthcare Providers & Services companies, Doximity ranks worse than 87.37% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Doximity's Future 3-5Y EPS without NRI Growth Rate is 6.42.
Doximity (NYSE:DOCS) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Doximity Future 3-5Y EPS without NRI Growth Rate Related Terms
DOCS vs PRVA, WAY, HTFL: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Health Information Services subindustry, Doximity's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doximity Future 3-5Y EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Doximity's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Doximity's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 6.42 mean?
Doximity (DOCS) has a Future 3-5Y EPS without NRI Growth Rate of 6.42 as of Aug. 24, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Doximity and its competitors. According to the industry distribution chart, Doximity ranks #173 out of 198 companies in the Healthcare Providers & Services industry, placing it in the top 87.4%.
Is Doximity's Future 3-5Y EPS without NRI Growth Rate too high?
Doximity's current Future 3-5Y EPS without NRI Growth Rate is 6.42. The Healthcare Providers & Services industry median Future 3-5Y EPS without NRI Growth Rate is 17.27. Doximity's value of 6.42 is 62.8% below this industry median. Based on the distribution chart, Doximity ranks #173 out of 198 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Doximity has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Doximity's Future 3-5Y EPS without NRI Growth Rate compare to PRVA and WAY?
According to the Healthcare Providers & Services industry distribution chart, Doximity ranks #173 out of 198 companies for Future 3-5Y EPS without NRI Growth Rate. This places Doximity in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 17.27. Doximity's value of 6.42 is 62.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median Future 3-5Y EPS without NRI Growth Rate among Healthcare Providers & Services companies is 17.27, based on 198 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Doximity's current Future 3-5Y EPS without NRI Growth Rate of 6.42 is 62.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Doximity and its competitors. For the Healthcare Providers & Services industry, the median Future 3-5Y EPS without NRI Growth Rate is 17.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Doximity's current Future 3-5Y EPS without NRI Growth Rate is 6.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doximity stock overvalued right now?
Based on GuruFocus' analysis, Doximity (DOCS) is currently considered Significantly Undervalued. The stock's GF Value™ is $45.46, compared to a current price of $25.33 — trading 44.3% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 6.42 and 62.8% below the Healthcare Providers & Services industry median of 17.27. Doximity's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Doximity (DOCS), the current Future 3-5Y EPS without NRI Growth Rate is 6.42 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doximity (DOCS) Overvalued in 2026?
Based on GuruFocus' analysis, Doximity stock appears to be undervalued.
The current stock price of $25.33 is trading 44.3% below its estimated GF Value™ of $45.46.
GuruFocus considers Doximity to be Significantly Undervalued.
Key valuation signals for DOCS:
Future 3-5Y EPS without NRI Growth Rate: 6.42
GF Value™: $45.46 vs. price of $25.33 (44.3% below fair value)
Industry Position: 62.8% below the Healthcare Providers & Services median (#173 of 198)
No single metric tells the full story. See the DOCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
86GF Score
Get the complete analysis for DOCS
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DOCS has been successfully added to your 
